Skip to main content

Advertisement

Table 2 Clinicopathological parameters and the expression of miR-204-5p in LUAD. Annotation: LUAD, lung adenocarcinoma. a, paired sample’s t test performed to compare miR-204-5p expression between NSCLC and the controls; Independent sample’s t test processed to assess relationships between miR-30d-5p expression and the clinicopathological parameters of NSCLC. TNM, tumor, node, metastasis; b, One-way ANOVA preformed to evaluate distributive feature of miR-204-5p in three or more groups of clinicopathological parameters

From: Downregulation of hsa-microRNA-204-5p and identification of its potential regulatory network in non-small cell lung cancer: RT-qPCR, bioinformatic- and meta-analyses

Clinicopathological parametersnRelevant expression of miR-204-5p (2−ΔCq)
Mean ± SDt/F-valuep-value
TissueLUAD1013.4663 ± 1.82397-2.731a0.007
Non-cancer1014.2786 ± 2.36824
GenderMale563.7768 ± 1.919371.9340.056
Female453.0800 ± 1.63729
Age (years)< 60413.7390 ± 1.850391.2450.216
> = 60603.2800 ± 1.79734
SmokeNo264.1000 ± 1.67141−0.6950.491
Yes184.4611 ± 1.72768
Tumor size<=3 cm533.0906 ± 1.72362−2.2180.029
> 3 cm483.8813 ± 1.85915
Vascular invasionNo704.1114 ± 1.632156.286< 0.001
Yes312.0097 ± 1.34123
TNMI-II443.8864 ± 1.871902.0660.041
III-IV573.1421 ± 1.73339
Lymph node metastasisNo454.0556 ± 1.868223.0270.003
Yes562.9929 ± 1.65660
Pathological gradingI174.2176 ± 1.941405.477b0.006
II613.6279 ± 1.81752
III232.4826 ± 1.36070